News
-
-
PRESS RELEASE
Original-Research: Cantourage Group SE (von NuWays AG): BUY
Cantourage Group SE published strong FY25 results, showing 82% yoy growth. Focus on premium strains in Germany, expanding in UK & Poland. FY26e sales to exceed €100m with improved margins. Valuation undemanding. Analyst maintains BUY rating with €10 PT -
-
PRESS RELEASE
Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets
Sandoz partners with Samsung Bioepis on up to five biosimilars, expanding its pipeline to 32 assets. The agreement aims to broaden patient access to high-quality medicines worldwide -
-
-
-
-
-
PRESS RELEASE
VERBUND AG: Full-year 2025 results: solid results despite below-average water supply and windfall tax
VERBUND AG reports solid full-year 2025 results despite challenges from below-average water supply and windfall tax, with EBITDA and Group result declining but remaining at a high level
